- Illumina Inc. (ILMN, Financial) and Tempus AI (TEM) announce a strategic partnership to revolutionize precision medicine through genomic AI innovation.
- The collaboration aims to enhance clinical adoption of next-generation sequencing tests, expanding molecular profiling to cardiology, neurology, and immunology.
- This initiative seeks to standardize molecular profiling and improve patient outcomes across various disease areas.
Illumina Inc. (ILMN) and Tempus AI, Inc. (TEM) have revealed a strategic partnership focused on harnessing genomic artificial intelligence to promote the clinical use of next-generation sequencing tests. This collaborative effort will integrate Illumina's advanced AI technologies with Tempus's robust multimodal data platform to enhance genomic algorithms and broaden molecular profiling across several disease categories beyond oncology, including cardiology, neurology, and immunology.
The objective is to generate compelling evidence to make comprehensive genomic profiling and molecular testing a standard practice across multiple disease domains, thereby addressing the gap where patients miss out on precision medicine benefits due to non-standardized molecular profiling. Through enhanced data analytics and sequencing technology, this partnership endeavors to improve patient outcomes and drive forward precision medicine research.
This new collaboration builds on the existing relationship between Illumina and Tempus, where both companies have been developing tools and assays to meet testing needs from early screening to therapy selection. By leveraging Tempus's extensive real-world data and Illumina's sequencing expertise, the partnership aims to accelerate advancements in precision medicine, potentially influencing clinical guidelines and encouraging broader adoption and reimbursement of comprehensive genomic profiling.
